Testing NEOK002 for Advanced Solid Tumors
Part of Cancer clinical trials.
This trial tests a new cancer drug called NEOK002 that targets two proteins (EGFR and MUC1) found on certain cancer cells. It's designed for patients with advanced cancers that have spread and don't have standard treatment options available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer must be locally advanced or metastatic (spread to other parts of body) with no standard therapy option
- You must have at least one tumor that can be measured on imaging scans
- You must be in good enough overall health to handle the study drug (ECOG performance status 0 or 1)
- Your blood, liver, and kidney function must be adequate
- You cannot have had a recent ADC drug (a type of targeted cancer drug) with a topoisomerase 1-inhibitor as your last treatment
- You cannot have brain metastases (cancer spread to the brain) or unstable brain involvement
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new cancer drug called NEOK001 that targets two proteins (B7-H3 and ROR1) found on certain tumor cells. The drug combines a cancer-fighting molecule with a toxic payload to kill cancer cells while sparing healthy tissue.
This trial tests a new drug called DM002 for people with advanced solid tumors that have not responded to standard treatments. The drug targets two proteins (MUC1 and HER3) found on some cancer cells, and may help shrink tumors or slow their growth.
This early-phase trial tests a new oral targeted drug, ND-003, for people with advanced solid tumors that have not responded to standard therapy. The study focuses on tumors with specific gene changes (NTRK or RET fusions), especially in the second part, to see if the drug can shrink tumors and be safe.
This trial tests a new drug called NV-001 for people with advanced solid tumors that are no longer responding to standard treatments. It aims to see if the drug is safe and can help shrink or slow tumor growth.
This trial tests a new drug that targets a protein called MET found on some cancer cells. It may help people with certain advanced cancers that have not responded to other treatments.
This trial tests a new drug called MC002 for advanced solid tumors that have not responded to standard treatments. The purpose is to find a safe dose and see if it can help shrink or control the cancer.
Hear when a new Locally Advanced (Unresectable) or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.